A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Dec 2016
At a glance
- Drugs Binimetinib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 05 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 05 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Mar 2018.